Results 241 to 250 of about 2,166,017 (392)
Author Correction: Oral immunotherapy combined with omalizumab for high–risk cow’s milk allergy: a randomized controlled trial [PDF]
Masaya Takahashi +9 more
openalex +1 more source
K. Palosuo +5 more
semanticscholar +1 more source
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger +6 more
wiley +1 more source
Impact of oral immunotherapy on diversity of gut microbiota in food-allergic children. [PDF]
Bouabid T +13 more
europepmc +1 more source
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo +10 more
wiley +1 more source
Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers [PDF]
Anne Marit Rykkelid +8 more
openalex +1 more source
Egg Oral Immunotherapy (OIT) Induces More Rapid Desensitization and Sustained Unresponsiveness (SU) in Egg-Allergic, Baked-egg Tolerant Children than the Addition of Daily Baked-egg Products [PDF]
Hugh A. Sampson +10 more
openalex +1 more source
Abstract Objective This study aimed to identify risk factors and develop a predictive scoring system for autoimmune‐associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE). Methods This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of
Simona Lattanzi +50 more
wiley +1 more source
Overcoming anaphylactic severe cow's milk allergy with slow and low-dose oral immunotherapy: A 10-year path to tolerance. [PDF]
Yamamoto S +3 more
europepmc +1 more source

